Show simple item record

dc.contributor.authorMolgaard-Hansen, L
dc.contributor.authorMöttönen, M
dc.contributor.authorGlosli, H
dc.contributor.authorJonmundsson, G K
dc.contributor.authorAbrahamsson, J
dc.contributor.authorHasle, H
dc.date.accessioned2011-02-16T09:24:55Z
dc.date.available2011-02-16T09:24:55Z
dc.date.issued2011-03
dc.date.submitted2011-02-16
dc.identifier.citationBr J Haematol. 2011, 152 (5):623-30en
dc.identifier.issn1365-2141
dc.identifier.pmid21241281
dc.identifier.doi10.1111/j.1365-2141.2010.08554.x
dc.identifier.urihttp://hdl.handle.net/2336/122050
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThe frequency and causes of treatment-related deaths (TRD) in second complete remission (CR2) in acute myeloid leukaemia (AML) were investigated in a historical, prospective cohort study of 429 children included in the Nordic Society of Paediatric Haematology and Oncology (NOPHO)-AML-88 and -93 trials. Relapse occurred in 158 children (39%). Seventeen (18%) of the 96 patients entering CR2 suffered TRD. The main causes were infection (59%) and complications from graft-versus-host disease (22%). Fourteen (82%) of 17 TRDs occurred in children undergoing haematopoietic stem cell transplantations (HSCT). Optimal supportive care after HSCT is essential, and studies on risk factors for TRD are needed.
dc.languageENG
dc.language.ison/aen
dc.publisherWiley-Blackwellen
dc.relation.urlhttp://dx.doi.org/10.1111/j.1365-2141.2010.08554.xen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocolsen
dc.subject.meshChilden
dc.subject.meshLeukemia, Myeloid, Acuteen
dc.subject.meshHeart Failureen
dc.subject.meshPubMed in processen
dc.titleTreatment-related deaths in second complete remission in childhood acute myeloid leukaemian/a
dc.typeArticleen
dc.contributor.departmentDepartment of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark Department of Paediatrics, University Hospital, Oulu, Finland Department of Paediatrics, Oslo University Hospital, Rikshospitalet, Oslo, Norway Department of Paediatrics, Landspitalinn University Hospital, Reykjavik, Iceland Department of Paediatric Oncology, The Queen Silvia Children's Hospital, Gothenburg, Sweden.en
dc.identifier.journalBritish journal of haematologyen
html.description.abstractThe frequency and causes of treatment-related deaths (TRD) in second complete remission (CR2) in acute myeloid leukaemia (AML) were investigated in a historical, prospective cohort study of 429 children included in the Nordic Society of Paediatric Haematology and Oncology (NOPHO)-AML-88 and -93 trials. Relapse occurred in 158 children (39%). Seventeen (18%) of the 96 patients entering CR2 suffered TRD. The main causes were infection (59%) and complications from graft-versus-host disease (22%). Fourteen (82%) of 17 TRDs occurred in children undergoing haematopoietic stem cell transplantations (HSCT). Optimal supportive care after HSCT is essential, and studies on risk factors for TRD are needed.


This item appears in the following Collection(s)

Show simple item record